Evidence map›Paper›PMID 42323784›Full record

ArticleRadiological physics and technology2026

In vivo dosimetry of cardiac implantable electronic devices with a radiophotoluminescent glass dosimeter in patients undergoing radiotherapy.

Shohei Mikasa, Hiroyuki Okamoto, Yuki Miura, Yusuke Watanabe, Toshimitsu Sofue, Satoshi Nakamura, Takahito Chiba, Kotaro Ijima, Tetsu Nakaichi, Mihiro Takemori and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Radiological physics and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shohei MikasaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroyuki OkamotoRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. hiokamot@ncc.go.jp.ORCID http://orcid.org/0000-0001-9491-787X
Yuki MiuraDepartment of Radiological Technology Radiological Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yusuke WatanabeDepartment of Radiological Technology Radiological Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Toshimitsu SofueDepartment of Radiological Technology Radiological Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Satoshi NakamuraRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takahito ChibaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kotaro IjimaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Tetsu NakaichiRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Mihiro TakemoriRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroki NakayamaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, 5- 1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Funding

National Cancer Center Research and Development Fund 2025-A-12
6 · The paper itself

Abstract

We aimed to establish and evaluate a method for measuring the cardiac implantable electronic devices (CIEDs) dose of radiotherapy patients using radiophotoluminescence glass dosimeters (RPLDs). Thirty-two treatment courses of thirty patients were analyzed. The relationships between the CIEDs dose and the treatment site locations were analyzed, and the RPLD doses were compared to the treatment planning system (TPS) doses for head and neck or chest cases (n = 18). A phantom study was conducted in five cases wherein the dose discrepancies between RPLD and TPS in all fractions were more than double and 5 cGy or more, and filter of energy dependence correction of RPLDs was evaluated. The longer the distance between the irradiation field and the CIEDs, the lower the doses, and it was approximated by a function of the power law of distance from the field edge. In eighteen cases where TPS and RPLD doses could be compared, the dose discrepancies per prescribed dose between RPLD measurements and TPS calculations were within 1.15%, with a 95% confidence limit of 0.6%. In the phantom study, the dose discrepancies between the RPLD and TPS were decreased using filters for all five cases. In conclusion, in vivo dosimetry using RPLD was very useful as a means of avoiding the following risks: when planning CT did not include the CIED for dose calculation-based assessment; unintended direct exposure of the CIED to the treatment beam; furthermore, TPS dose calculation accuracy outside of the irradiated field remains an issue.

Indexed as

GlassIn Vivo DosimetryLuminescenceProstheses and ImplantsRadiation DosimetersRadiometryFemaleHumansPhantoms, ImagingRadiotherapy DosageCardiac implantable electronic deviceIn vivo dosimetryRadiophotoluminescence glass dosimeterRadiotherapy

Identifiers

PMID42323784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.